Бетті таңдаңыз

Kicking off the New Year with exciting research news!

Янв 6, 2021 | Жаңалықтар, Санатсыз

Happy New Year! We hope everyone had a healthy, restful holiday.

We are kicking off 2021 off with more exciting research news. In January, the science journal Табиғат published breakthrough results demonstrating that genetic editing in a mouse model of Progeria corrected the mutation that causes Progeria in many cells, improved several key disease symptoms and dramatically increased lifespan in the mice.

PRF бірігіп қаржыландырған және PRF медициналық директоры доктор Лесли Гордонмен бірлесіп жазған зерттеу ауру тудыратын мутацияны түзетуге бағдарламаланған базалық редактордың бір рет инъекциясы арқылы тышқандар емделмеген Progeria тышқандарына қарағанда 2,5 есе ұзақ өмір сүретінін көрсетті. сау тышқандардағы кәріліктің басталуымен сәйкес келетін жасқа. Маңыздысы, емделген тышқандар сау тамыр тінін де сақтап қалды - бұл маңызды нәтиже, өйткені тамырлардың тұтастығын жоғалту Прогериясы бар балалардағы өлімнің болжамы болып табылады.

The study was co-led by world expert in genetic editing, David Liu, PhD, of the Broad Institute, MIT, Cambridge, MA, Jonathan Brown, Assistant Professor of Medicine in the Division of Cardiovascular Medicine at Vanderbilt University, and Francis Collins, MD, PhD, Director of the National Institutes of Health.

To see this dramatic response in our Progeria mouse model is one of the most exciting therapeutic developments I have been part of in 40 years as a physician-scientist,” said Dr. Collins.
Dr. Francis Collins

Director of the National Institutes of Health.

Five years ago, we were still finishing the development of the very first base editor,” said Dr. Liu. “If you had told me then that within five years, a single dose of a base editor could address Progeria in an animal at the DNA, RNA, protein, vascular pathology, and lifespan levels, I would have said ‘there’s no way.’ It’s a real testament to the dedication of the team that made this work possible.
David Lui, PhD

Broad Institute, MIT

Additional preclinical studies are needed to investigate these results, which we hope will one day lead to a clinical trial. We look forward to keeping you informed of this exciting finding as further progress is made!

Read more about this thrilling news Мұнда.

As we enter 2021, we are grateful for partners like YOU, who make this kind of progress possible.

Last year alone, The Progeria Research Foundation:

  • Achieved a major milestone with the first-ever FDA-approved treatment for Progeria, lonafarnib;
  • Brought children with Progeria from around the world to Boston Children’s Hospital for the PRF-funded clinical trial (when travel was allowed due to COVID 19);
  • Held our 10th International Progeria Scientific Workshop, bringing together a record 370 registrants from 30 countries in our first-ever web-based scientific meeting;
  • Continued in earnest with our key programmatic activities that will lead us to treatments and the future cure!

Koblan LW, Erdos MR, Wilson C, Cabral WA, Levy JM, Iong, ZM, Tavarez UL, Davison L, Gete YG, Mao X, Newby GA, Doherty SP, Narisu N, Sheng Q, Krilow C, Lin CY, Gordon LB,  Cao K, Collins FS, Brown JD, Liu DR. In Vivo Adenine Base Editing Rescues Hutchinson-Gilford Progeria Syndrome Nature. 2021 Jan 6

kkKazakh
en_USEnglish arArabic bn_BDBengali zh_CNChinese nl_NLDutch fr_FRFrench de_DEGerman he_ILHebrew hi_INHindi id_IDIndonesian it_ITItalian knKannada ko_KRKorean mrMarathi psPashto pt_PTPortuguese ru_RURussian es_ESSpanish ta_INTamil ukUkrainian urUrdu kkKazakh